The study, conducted by the Korea Disease Control and Prevention Agency in South Korea, involved 499 medical workers. One hundred people received one shot of each vaccine, 200 got two doses of Pfizer’s shot, and the rest got two doses of AstraZeneca’s shot.
The results showed that those who got the combination of shots had the same number of neutralizing antibodies as those who got two Pfizer shots, according to The Hill.
The study could lead to countries combining AstraZeneca’s shot with an mRNA vaccine to improve results, The Hill reported. AstraZeneca’s shot is used widely in many countries, but isn’t approved in the U.S.
A separate study conducted in June by British scientists showed that a combination of AstraZeneca and Pfizer’s shots produce the best T-cell and antibody response to COVID-19, The Hill reported.
Read the full article here.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
